All funding is not personal but goes to the independent research fund of the Department of Dermatology of Radboud University Medical Center Nijmegen (Radboudumc), the Netherlands. EMGJdJ has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Pfizer, Novartis, Janssen Pharmaceuticals, and Leo Pharma, and has acted as consultant or paid speaker for or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen, Novartis, Lily, Celgene, Leo Pharma, UCB, and Almirall. JMPAvdR carries out clinical trials for AbbVie, Celgene, and Janssen has received speaking fees/attended advisory boards from AbbVie, Bristol Myers Squibb, Leo Pharma, Almirall, and Janssen and has received reimbursement for attending a symposium from Janssen, Pfizer, Celgene, and AbbVie. Ĭonflicts of Interest: TWvH has acted as a paid speaker for Lily Eli and has received reimbursement for attending a symposium from UCB. Originally published in JMIR Research Protocols (). ©Tamara W van Hal, Juul MPA Van den Reek, Hans MM Groenewoud, Marcel C Pasch, Frank HJ Van den Hoogen, Mark H Wenink, Elke MGJ De Jong. International registered report identifier (irrid): To predict the development of PsA in the future, longitudinal/prospective data collection is required and will be performed in a follow-up study (DAPPER-i). Although internal validity will be tested, external validity will have to be checked using a second validation cohort. The DAPPER study is specifically designed to improve the detection of existing PsA in a dermatologic outpatient setting. Follow-up with newly discovered patients with PsA is ongoing. Inclusion started in June 2019 and finished in June 2021. The screening visit will be used to gather demographical and medical data, which can later be used to develop the aforementioned screening instrument. After 1 year, data on changes in quality of life and PsA and psoriasis disease activity will be collected from the referred patients. If there is clinical suspicion of PsA and the patient is not yet treated by a rheumatologist, referral to the Department of Rheumatology will follow for confirmation of the diagnosis and further care. Patients with psoriasis (N=300) who are treated at an outpatient dermatological clinic will be screened extensively for signs and symptoms of PsA by a trained rheumatologist. The Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) study is designed to determine the prevalence of PsA in a psoriasis population and to find parameters that can be used to develop a new or enhance an existing instrument for a rheumatological referral.ĭAPPER is a longitudinal observational study with a 1-year follow-up. However, current methods used to screen patients with psoriasis for those who might benefit from referral to a rheumatologist are not performing well enough. Timely recognition and referral to a rheumatologist are therefore key. If left untreated, this can lead to pain, impaired function, and irreversible joint damage. One in three patients with psoriasis will develop psoriatic arthritis (PsA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |